However, if a rearrangement would lead to a frameshift mutation or to a non-expressed ALK variant the antibody would not identify the tumor as “positive”, although the sample could be positive by FISH and, thus, be eligible for Crizotinib therapy, and vice versa. This evidence concerns the gene ALK and neoplasm.